Navigation Links
Antibiotic use in infants before 6 months associated with being overweight in childhood
Date:8/21/2012

New York City (August 21, 2012) Treating very young infants with antibiotics may predispose them to being overweight in childhood, according to a study of more than 10,000 children by researchers at the NYU School of Medicine and the NYU Wagner School of Public Service and published in the online August 21, 2012, issue of the International Journal of Obesity.

The study found that on average, children exposed to antibiotics from birth to 5 months of age weighed more for their height than children who weren't exposed. Between the ages of 10 to 20 months, this translated into small increases in body mass percentile, based on models that incorporated the potential impacts of diet, physical activity, and parental obesity. By 38 months of age, exposed children had a 22% greater likelihood of being overweight. However, the timing of exposure mattered: children exposed from 6 months to 14 months did not have significantly higher body mass than children who did not receive antibiotics in that same time period.

The NYU School of Medicine researchers, led by Leonardo Trasande, MD, MPP, associate professor of pediatrics and environmental medicine, and Jan Blustein, MD, PhD, professor of population health and medicine, caution that the study does not prove that antibiotics in early life causes young children to be overweight. It only shows that a correlation exists. Further studies will need to be conducted to explore the issue of a direct causal link.

"We typically consider obesity an epidemic grounded in unhealthy diet and exercise, yet increasingly studies suggest it's more complicated," said Dr. Trasande. "Microbes in our intestines may play critical roles in how we absorb calories, and exposure to antibiotics, especially early in life, may kill off healthy bacteria that influence how we absorb nutrients into our bodies, and would otherwise keep us lean."

In recent years there has been a growing concern about the overu
'/>"/>

Contact: lorinda klein
lorindaann.klein@nyumc.org
212-404-3533
NYU Langone Medical Center / New York University School of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Danger in the blood: U-M scientists show how antibiotic-resisting bacterial infections may form
2. First antibiotic stewardship probed in the Journal of the Pediatric Infectious Diseases Society
3. Vaccine and antibiotics stabilized so refrigeration is not needed -- NIH study
4. Toward an alternative for antibiotics to fight bacterial infections?
5. The effect of treatment with antibiotics and vaccination against Q fever in sheep
6. How one strain of MRSA becomes resistant to last-line antibiotic
7. Bacteria discovery could lead to antibiotics alternatives
8. University of Nevada, Reno first to show transgenerational effect of antibiotics
9. Hot on the trail of metabolic diseases and resistance to antibiotics
10. New antibiotic could make food safer and cows healthier
11. Team discovers how bacteria resist a Trojan horse antibiotic
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/8kmfcn/iphone_5s ) ... 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with ... device of Apple incorporating such a feature, called ...
(Date:12/19/2014)... , Dec. 18, 2014   LaunchKey , the ... the post-password and Internet of Things era, today announced ... The venture round was led by Metamorphic Ventures with ... Venture Partners, VegasTechFund, and others.  LaunchKey has raised $4 ... to expand its team and bring LaunchKey to market ...
(Date:12/17/2014)... Dec. 15, 2014  HITLAB SM announced ... (GCP) audit to confirm its adherence to current ... accomplishment enables HITLAB to conduct regulated smart device ... principles for patient safety and research quality. ... access, quality, and delivery with innovative technology," said ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... high blood pressure drugs may be useful in preventing and ... people with diabetes. The study, the largest to date on ... prevent or treat the sight-threatening disease, they say. The findings ... monthly publication. Edward Feener and colleagues point out ...
... Pneumonia A group led by Dr. James ... Human Infectious Diseases Research of The Methodist Hospital Research ... Paton-Valentine leukocidin (PVL) does not affect methicillin-resistant Staphlococcus ... can be found in the March 2010 issue of ...
... -- Oak Ridge National Laboratory researchers will lead projects ... processor hours of computing time on supercomputers located at ... awards were made through the U.S. Department of Energy ... Experiment (INCITE) program. This year, the INCITE program will ...
Cached Biology News:Tips from the American Journal of Pathology 2Tips from the American Journal of Pathology 3Tips from the American Journal of Pathology 4Tips from the American Journal of Pathology 52010 DOE INCITE projects allocated at ORNL 22010 DOE INCITE projects allocated at ORNL 32010 DOE INCITE projects allocated at ORNL 4
(Date:12/24/2014)... Dec. 23, 2014 China Biologic Products, ... a leading fully integrated plasma-based biopharmaceutical company in ... its majority-owned subsidiary, Shandong Taibang Biological Products Co. ... from the China Food and Drug Administration (the ... As previously disclosed in the Company,s public filings, ...
(Date:12/24/2014)... Fla. , Dec. 23, 2014  Rock Creek ... that it has filed a Clinical Trial Application (CTA) ... Healthcare products Regulatory Agency (MHRA) seeking regulatory approval to ... lead molecule, Anatabine Citrate. Contingent on the ... conduct a Phase I trial to assess the safety, ...
(Date:12/22/2014)... /PRNewswire/ - RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSX.V: ... the development of autologous cell therapies, announced today the ... Calgary in conjunction with co-authors from Kyoto University and ... company,s ongoing clinical research using dermal sheath cup (DSC) ... The paper entitled " Hair Follicle Dermal Stem ...
(Date:12/22/2014)... The American Journal of Hematology/Oncology, ... reviews and editorials addressing developments and pathways related ... a provocative article exploring the role of follicle-stimulating ... treatment of prostate cancer. , The article ... possibility that there could be a connection to ...
Breaking Biology Technology:China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 2Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 3Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 4Newly Released Peer-Reviewed Publication Further Validates RepliCel's Use of Dermal Sheath Cup Cells to Treat Pattern Baldness 5Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 2Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 3Prostate Cancer Experts Dissect the Role of Follicle-stimulating Hormone in the Development, Progression and Potential Treatment of Prostate Cancer 4
... Biosciences,Corporation (Nasdaq: MATK ) today announced that ... Wilmington, Delaware, has ruled on various,post-trial motions and ... the defendants in the patent infringement suit brought ... Nutrition Specialties &,Food Ingredients GmbH. The suit involves ...
... Nov. 1 ThermoGenesis,Corp. (Nasdaq: KOOL ), a ... store, and administer therapeutic doses of,adult stem cells for ... financial results for the fiscal first quarter ended September,30, ... Call and Webcast Management will host a conference ...
... technical feasibility of ... ... TSX symbol: SBS, CALGARY, Nov. 1 /PRNewswire-FirstCall/ - ... for metabolic and cardiovascular diseases, today announced its,2007 third quarter operational ...
Cached Biology Technology:Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 2Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge 3ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 2ThermoGenesis Corp. to Announce First Quarter Fiscal 2008 Results on November 8, 2007 3SemBioSys announces 2007 third quarter results 2SemBioSys announces 2007 third quarter results 3SemBioSys announces 2007 third quarter results 4SemBioSys announces 2007 third quarter results 5SemBioSys announces 2007 third quarter results 6SemBioSys announces 2007 third quarter results 7SemBioSys announces 2007 third quarter results 8SemBioSys announces 2007 third quarter results 9SemBioSys announces 2007 third quarter results 10SemBioSys announces 2007 third quarter results 11SemBioSys announces 2007 third quarter results 12
Guanine nucleotide-binding protein G(k), alpha subunit...
ICAD Purified Anti-Mouse clone Polyclonal, Isotype Rabbit Ig, 200 µl Consult technical datasheet for details....
Indoleamine 2,3-dioxygenase [IDO]...
Recognizes the 41 and 43 kDa G-proteins present in liver plasma membranes and Gq/11alpha expressed in the Sf9 insect cell expression system. Negative for recombinant G(I)alpha subtypes....
Biology Products: